Cyberheart
Founded Year
2006Stage
Acquired | AcquiredTotal Raised
$14.77MExpert Collections containing Cyberheart
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cyberheart is included in 3 Expert Collections, including Robotics.
Robotics
1,801 items
This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.
Medical Devices
8,293 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,900 items
Cyberheart Patents
Cyberheart has filed 20 patents.
The 3 most popular patent topics include:
- Medical physics
- Radiation therapy
- Cardiac arrhythmia
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/30/2020 | 2/8/2022 | Cardiac arrhythmia, Radiation therapy, Medical physics, Radiobiology, Cardiac electrophysiology | Grant |
Application Date | 9/30/2020 |
|---|---|
Grant Date | 2/8/2022 |
Title | |
Related Topics | Cardiac arrhythmia, Radiation therapy, Medical physics, Radiobiology, Cardiac electrophysiology |
Status | Grant |
Latest Cyberheart News
May 13, 2019
May 13, 2019 Varian is taking a dive into the emerging world of cardiac radioablation through the acquisition of CyberHeart. The purchase of the privately-held company includes the transfer of intellectual property and patents covering the use of radiation for the heart to Varian which believes based on early positive clinical findings that the technology can assist cardiac arrhythmia patients. Story Continues Below Advertisement We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED "This is a new area and Varian is excited about the potential application of stereotactic radioablation to the cardiac space - specifically treating patients who are suffering from irregular heartbeats," Dr. Dee Khuntia, chief medical officer at Varian, told HCB News. "Based on the articles we have seen in the New England Journal of Medicine and in Circulation, we are enthused about this space." “We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space." Varian views its venture into cardiac ablation as an expansion of its focus on patient-centered innovation, and is now in the midst of prioritizing development and clinical trials going forward. Cardiac ablation technology, however, is not yet approved by the FDA, as it still requires premarket approval (PMA), which subsequently requires additional clinical evidence as support. "Varian has a long track record of innovations in the field of radiation medicine and has successfully commercialized radiosurgery technology for treating both benign and malignant lesions," said Khuntia. “We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space." Though the transfer of IP and software tools is part of the acquisition, no employees from CyberHeart will be joining Varian. No financial details were disclosed.
When was Cyberheart founded?
Cyberheart was founded in 2006.
Where is Cyberheart's headquarters?
Cyberheart's headquarters is located at 707 Menlo Avenue, Menlo Park.
What is Cyberheart's latest funding round?
Cyberheart's latest funding round is Acquired.
How much did Cyberheart raise?
Cyberheart raised a total of $14.77M.
Who are the investors of Cyberheart?
Investors of Cyberheart include Varian Medical Systems, United Investments, Emergent Medical Partners, Mitsubishi Corporation Life Sciences Ventures, MC Financial Services and 4 more.
Who are Cyberheart's competitors?
Competitors of Cyberheart include Angel Medical Systems, Cameron Health, PEAK Surgical, DIRAmed, OrSense and 11 more.
You May Also Like
NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.
OrSense provides non-invasive monitoring of various blood constituencies.
InnerPulse develops minimally invasive devices for cardiac rhythm management
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment.Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.
Advanced Surgical Concepts develops surgical instruments for use in endoscopy and in minimally invasive surgery
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.